Simple blood test may predict immunotherapy success in lung cancer
NCT ID NCT07363811
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is looking at whether large granular lymphocytes (LGLs), a type of immune cell, can predict how well patients with advanced non-small cell lung cancer respond to the immunotherapy drug nivolumab. Researchers will measure LGL levels in 50 patients before and during treatment and compare them to tumor response and survival. The goal is to find a simple blood test that helps guide treatment decisions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could help doctors predict which lung cancer patients will benefit most from nivolumab, leading to more personalized treatment.
What could go wrong
This is a small, early observational study (50 participants) that only looks for a link between LGLs and outcomes. It does not test a new treatment, so it may not change practice.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC NSCLC - NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Necmettin Erbakan University Faculty of Medicine, Department of Medical Oncology
RECRUITINGKonya, Meram, 42090, Turkey (Türkiye)
Contact Phone: •••-•••-•••• Email: •••••@•••••